Fundraising Fox
/Companies
Sign in

Codagenix

Farmingdale, US · Founded 2011 · Delaware corporation · 18 employees on LinkedIn · 4 known investors

Find your way into Codagenix

Sign up to see every warm intro you have to Codagenix

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Codagenix team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses. The company applies this platform in clinical development, drawing on expertise in virology, computational science, and patient care.

BiotechDeep TechHealthtech

Founders & leadership

Codagenix was founded in 2011 by John Robert Coleman and Steffen Mueller.

JR
John Robert ColemanCo-founder
SMSteffen Mueller
Steffen MuellerFounder, President, Chief Scientific OfficerMueller founded Codagenix in 2009 and has also served as its president. His academic work includes a research assistant professorship at Stony Brook University, where he remains a voluntary assistant professor of research, and an earlier research fellowship from the Boehringer Ingelheim Fonds.
CP
Charlie PettyNamed on SEC filing
SW
Steven WinickNamed on SEC filing
JH
Jill HoweNamed on SEC filing
PGPaul Grint
Paul GrintExecutive Chairman & Interim CEOGrint has led several biopharmaceutical companies, serving as CEO of AmpliPhi Biosciences and as President and CEO of Regulus Therapeutics. He also chairs CRISPR QC, is an entrepreneur in residence at the University of California San Diego, and has served on the boards of Persephone Biosciences, Inhibikase Therapeutics, and Synedgen.
TCTyler Cook
Tyler CookNamed on SEC filing
LR
Lori Rudolph-OwenNamed on SEC filing

Board

GRGlenn Rockman
Glenn RockmanDirectorCo-Founder and Partner at Adjuvant Capital

Investors · 4

In-Q-Tellisted by In-Q-TelTysons · $100K – $2.5M

How we know: In-Q-Tel's portfolio page · Not right? Tell us

Topspin PartnersreportedMamaroneck · $10M – $50M

How we know: funding news · biospace.com · Not right? Tell us

Also in the syndicate · 1

Euclidean Capital

Funding

SEC filings, press & company announcements

$45M disclosed across 2 of 3 rounds · 2020–2023

▶$25MraisedFeb 2023 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charlie PettyDirector
  • Steven WinickDirector
  • Jill HoweDirector
  • John Robert ColemanExecutive Officer, Director
  • Steffen MuellerDirector
  • Paul GrintDirector
  • Glenn RockmanDirector
  • Tyler CookExecutive Officer
  • Lori Rudolph-OwenDirector
Offering amount
$25M
Amount sold
$25M
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

GigaGenGigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.

Companies working in the same space as Codagenix.

Non-dilutive funding · 13 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$999.3K
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$3.9M
U.S. ArmyArmyPhase II2019$947.6K
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.5M
Department of Agriculture (USDA)Phase II2017$592.9K
U.S. ArmyArmyPhase I2017$148.9K
Department of Agriculture (USDA)Phase II2016$597.7K
Department of Agriculture (USDA)Phase I2016$99.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$222.7K
Department of Agriculture (USDA)Phase I2015$99.8K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2014$596.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$399.8K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2012$600K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products - BioSpacebiospace.com · Jan 2020

Frequently asked questions

What does Codagenix do?
Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses. The company applies this platform in clinical development, drawing on expertise in virology, computational science, and patient care.
Who founded Codagenix?
Codagenix was founded by John Robert Coleman, Steffen Mueller in 2011.
Who are Codagenix's investors?
Codagenix's investors include Adjuvant Capital, In-Q-Tel, Topspin Partners.
How much funding has Codagenix raised?
Codagenix has disclosed $45M raised across 2 of its 3 known rounds.
Where is Codagenix headquartered?
Codagenix is headquartered in Farmingdale, US.